Skip to main content
Premium Trial:

Request an Annual Quote

Patrick Balthrop, Tom Erickson, Charles Powell, David U Prichard, and David McCarty

Premium

Luminex has announced that Patrick Balthrop will serve as the company’s new CEO and president. Balthrop will replace Tom Erickson, who had been serving as the company’s interim CEO and president since Sept. 2002.

Prior to his appointment with Luminex, Balthrop was the president of Fisher Healthcare, a division of Fisher Scientific International. Before that, he worked for more than 20 years with Abbott Laboratories in various leadership positions, Luminex said.

Balthrop has an MBA from the Kellogg Graduate School of Management of Northwestern University, and holds a BS in biology from Spring Hill College.


Aurora Discovery said that Charles Powell has joined the company as vice president of sales and marketing. Powell will be responsible for leading sales intitatives, forging strategic relationships with customers, and marketing the company’s microplate and microfluidic workstation products, Aurora said.

Powell has held several senior sales and marketing positions in the biotechnology industry, including 12 years in various roles at Beckman Coulter.


Invitrogen’s stockholders have named David U’Prichard to its board of directors, Invitrogen said last week.

U’Prichard currently serves as a venture partner with Apax Partners and as president of Druid Consulting. Prior to this, he was the CEO of 3-Dimensional Pharmaceuticals, overseeing the company’s IPO and eventual acquisition by Johnson and Johnson. He has also held management positions at SmithKline Beecham and ICI/Zeneca.

U’Prichard earned his PhD in pharmacology from the University of Kansas, and has held various academic appointments at Northwestern University Medical School, Johns Hopkins University, University of Maryland, and University of Pennsylvania.

Invitrogen said that David McCarty will rotate off the board of directors after having served for nearly five years.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.